Pfizer beats Sanofi to buy Medivation for US$14b
It gains cancer drug Xtandi with acquisition; analysts project it to generate US$1.33b in annual sales by 2020
New York
PFIZER Inc has agreed to buy Medivation Inc for about US$14 billion, gaining a blockbuster prostate cancer treatment and leaving French drugmaker Sanofi jilted.
Pfizer will pay US$81.50 a share in cash, the companies said in a statement on Monday. Shares of Medivation, which closed at US$67.16 last Friday, climbed about 20 per cent to US$80.57 in early US trading.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue